GlassScriptPhysician profile
Raj N Nagaraj
NPI 1104935147
$7,906.60
in general payments reported to CMS, 2019-2025
57 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $1,295 · 2021: $935 · 2022: $964 · 2023: $958 · 2024: $1,166 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184 · Gift: $59.40 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.75 |
| Gift | $59.40 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $585.09 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $456.76 | 2019-2025 | Repatha, Tepezza, Evenity |
| Sanofi-Aventis U.S. LLC | $423.70 | 2019-2025 | |
| Abbott Laboratories | $422.09 | 2019-2025 | Freestyle Libre 3, Eterna |
| Mannkind Corporation | $365.83 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $360.10 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $358.92 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.12 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $279.33 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $253.47 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $246.17 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $233.36 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $223.76 | 2019-2024 | Unithroid |
| Novartis Pharmaceuticals Corporation | $183.40 | 2023-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $176.62 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Horizon Therapeutics Plc | $169.84 | 2019-2023 | Tepezza |
| Insulet Corporation | $162.75 | 2019-2025 | Omnipod |
| Dexcom, INC. | $162.18 | 2019-2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $144.08 | 2019-2025 | Strensiq |
| Ibsa Pharma INC. | $131.30 | 2019-2025 | Licart, Tirosint, Tirosint |
| Radius Health, INC. | $123.25 | 2019-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $109.48 | 2021-2025 | |
| Lifescan, INC. | $91.57 | 2019-2022 | |
| Beta Bionics, INC. | $89.79 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Janssen Pharmaceuticals, INC | $86.78 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $76.36 | 2021-2023 | |
| Chiesi USA, INC. | $75.36 | 2024-2025 | Mycapssa |
| Neurocrine Biosciences, INC. | $70.84 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $70.66 | 2020-2021 | |
| Amryt Pharma Holdings LTD | $62.67 | 2022-2023 | Mycapssa |
| Pfizer INC. | $56.67 | 2019-2025 | |
| Esperion Therapeutics, INC. | $53.71 | 2021-2024 | Nexletol |
| Currax Pharmaceuticals LLC | $53.32 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $49.19 | 2025 | Yorvipath |
| Antares Pharma, INC. | $48.49 | 2022-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $46.23 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $42.29 | 2022-2024 | Isturisa |
| Nalpropion Pharmaceuticals LLC | $39.02 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.14 | 2019 | |
| Zealand Pharma US, INC. | $31.86 | 2020-2021 | |
| Shire North American Group INC | $30.23 | 2019 | |
| Cequr Corporation | $29.56 | 2023-2024 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $27.67 | 2024 | |
| Soleno Therapeutics, INC. | $21.74 | 2025 | Vykat Xr |
| Clarus Therapeutics INC. | $21.21 | 2021 | |
| Averitas Pharma INC. | $20.40 | 2023 | Qutenza |
| Companion Medical, INC. | $19.90 | 2020 | |
| Kyowa Kirin, INC. | $19.50 | 2025 | |
| Eusa Pharma (US) LLC | $18.94 | 2022 | |
| Eisai INC. | $18.71 | 2019 | |
| Vivus LLC | $18.53 | 2019 | |
| Nevro Corp. | $16.47 | 2024 | Senza |
| Sequel Med Tech, LLC | $15.81 | 2025 | Twiist |
| Acella Pharmaceuticals, LLC | $15.04 | 2025 | NP Thyroid 60 |
| Valeritas, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Nagaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.